The mixture of features of CanSinoBIO and Sinovac COVID induces a stronger response than the study of Sinovac alone.

by

BEIJING, Sept. 7 (Reuters) – A Chinese study studying the COVID-19 vaccine blend showed that receiving a booster vaccine from the CanSino Biologics vaccine after one or two doses of the Sinovac Biotech vaccine (SVA.O ) gave a much stronger antibody response than using the Sinovac trait as a booster.

The study, among the first analyzes in China that combines different COVID-19 vaccines, comes when the country said it would use booster shots in specific groups amid concerns about declining vaccine protection over the course of the time.

Participants who received a booster dose of CanSinoBIO (6185.HK) three to six months after a second shot from Sinovac showed a jump of 78 times on average when neutralizing antibody levels two weeks later, according to a document published Monday before a peer review.

In contrast, those who received a booster shot from Sinovac showed a 15.2-fold increase in neutralizing antibody levels, according to researchers from local disease control authorities, CanSinoBIO and other Chinese institutions.

A dose of Sinovac followed by a CanSinoBIO booster at one or two month intervals resulted in a 25.7-fold increase in neutralizing antibody levels, while two doses of Sinovac induced a 6.2-fold increase. .

The study analyzed data from about 300 healthy adults aged 18 to 59 years.

The study did not evaluate the protection of the impellers against COVID-19 and did not test the neutralizing antibody against the more transmissible Delta variant, according to the document.

More than 1.4 billion doses of the Sinovac vaccine have been administered worldwide, about three-quarters of them in China.

China, which has kept local infections under control, has completely vaccinated about 69% of its population as of Sept. 6. He said a total of 2.1 billion doses had been administered as of Tuesday as of Monday.

Report by Roxanne Liu and Ryan Woo; Edited by Miyoung Kim and Susan Fenton

Our standards: the principles of trust of Thomson Reuters.

.Source